Milestone Pharmaceuticals NASDAQ: MIST said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibrillation with rapid ventricular rate. Get MIST alerts: Oliveto said Milestone made the product available through retail pharmacies by the end of January and began promotion in earnest in mid-February, including de ...

Roivant Sciences (NasdaqGS:ROIV) 2026 Conference May 13, 2026 01:00 PM ET Speaker2 Let's get started. Good morning, everyone. Thanks for joining the BofA Healthcare Conferences. My name is Qi Fang. I have Madina Ramadhan with me today. We are both from the U.S. Biopharmaceutical Healthcare team here at Bank of America. I cover Roivant, she covers Immunovant, and we are glad to be co-hosting CEO of Roivant, Matt Gline, today. Thanks for joining us, Matt. Speaker1 I'm so happy to be here. Thank you. Speaker2 ...